|Place of Origin:||CHINA|
|Model Number:||Pneumonia Treatment Drugs - 7|
|Minimum Order Quantity:||25KGS|
|Packaging Details:||Aluminum foil bag , fiber can , kraft paper bag , plastic drum , 1kg/ bag or 25kg/ drum or as required|
|Delivery Time:||Within 7 days|
|Payment Terms:||T/T, Western Union|
|Supply Ability:||200-300 MTS/month|
|Molecular Weight:||720.96||Type:||Pneumonia Treatment Drugs|
anti pneumonia drugs,
Ritonavir CAS 155213-67-5 Pneumonia Treatment Drugs
Lopinavir / ritonavir have been listed in China for a long time and are mainly used in the treatment of AIDS. The main drug of lopinavir is to combine with virus protease to make the virus particles produced immature and non infectious; while ritonavir can inhibit the metabolism of lopinavir in liver, thus improving the blood concentration of lopinavir and playing a synergistic role.
|Appearance||White to off-white powder||White powder|
|Residue on ignition||NMT 0.2%||0.10%|
|Heavy metals||NMT 20 ppm||Conforms|
|Sulphated ash||NMT 0.105||0.03%|
|Assay (by HPLC)||98.0%~102.0%||99.00%|
Related products:CAS 192725-17-0
This product is suitable for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults and children over 2 years old with other antiretroviral drugs.
The experience of using lopinavir and tonavir is mainly from patients who have not received antiretroviral therapy. Data on patients who have been treated with protease inhibitors are very limited. There are also very limited data on remedial treatment in the case of failure of lopinavir.
Whether HIV-1 patients who have been treated with protease inhibitors choose this drug or not depends on two factors: the results of individual virus resistance test and the treatment history.
The novel coronavirus pneumonia treatment plan (trial version third) was released in January 22, 2020, and patients can be treated with R-B or ritonavir.
We can customize according to customer's requirement.
If you have any question pls mail us or call us.